This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jubb, A. M. Articles by Koeppen, H. Search for Related Content PubMed PubMed Citation Articles by Jubb, A. M. Articles by Koeppen, H.

EphB2 is a Prognostic Factor in Colorectal Cancer

Authors' Affiliations: Departments of ¹ Pathology and ² Molecular Oncology, Genentech, Inc., South San Francisco, California; ³ Academic Unit of Pathology, University of Leeds, United Kingdom; and ⁴ Institute of Pathology, Starnberg, Germany

Requests for reprints: Adrian Jubb, Department of Pathology, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080. Phone: 650-225-6902; Fax: 650-225-8989; E-mail: adrianjubb{at}gmail.com.

A receptor tyrosine kinase for ephrin ligands, EphB2 is expressed in colorectal cancer and has been proposed as a target for immunoconjugate therapy. The aim of this study was to perform a detailed histologic analysis of EphB2 expression in normal and neoplastic colorectal tissues. In addition, we sought to evaluate EphB2 expression as a prognostic factor in colorectal cancer. Expression of EphB2 was examined in normal colon (n = 28), colorectal cell lines (n = 20), colorectal adenomas (n = 148), primary cancers (n = 28), and metastases (n = 39) using immunohistochemistry. In addition, a series of primary cancers and matched normal (n = 342) with outcome data were profiled in tissue microarrays. The intensity of EphB2 expression was assessed in the entire series by immunohistochemistry, and in a subset by in situ hybridization. Overall survival and recurrence-free survival were correlated with EphB2 protein expression in retrospective subset analyses. Epithelial EphB2 expression was shown at all stages of colorectal tumorigenesis, including the base of all normal crypts, 77% of adenomas, 82% of primary cancers, and 64% of metastases. Although homogeneous expression was observed in adenomas, the pattern of staining was focal (mean 25%) in most malignant lesions. Patients whose tumor stained 2+ for EphB2 expression (versus 0/1+) exhibited significantly prolonged overall survival: mean duration of survival, 2,514 versus 1,044 days; hazard ratio, 0.45; 95% confidence interval, 0.18 to 0.95 (P = 0.035). In summary, EphB2 is expressed in normal crypts, colorectal adenomas, primary cancers, and metastases. High levels of EphB2 expression are associated with a longer mean duration of survival in colorectal cancer.

This article has been cited by other articles:

				J. E. Chrencik, A. Brooun, M. I. Recht, G. Nicola, L. K. Davis, R. Abagyan, H. Widmer, E. B. Pasquale, and P. Kuhn Three-dimensional Structure of the EphB2 Receptor in Complex with an Antagonistic Peptide Reveals a Novel Mode of Inhibition J. Biol. Chem., December 14, 2007; 282(50): 36505 - 36513. [Abstract] [Full Text] [PDF]

				R. J. Pelham, L. Rodgers, I. Hall, R. Lucito, K. C. Q. Nguyen, N. Navin, J. Hicks, D. Mu, S. Powers, M. Wigler, et al. Identification of alterations in DNA copy number in host stromal cells during tumor progression PNAS, December 26, 2006; 103(52): 19848 - 19853. [Abstract] [Full Text] [PDF]

				V. Davalos, H. Dopeso, J. Castano, A. J. Wilson, F. Vilardell, J. Romero-Gimenez, E. Espin, M. Armengol, G. Capella, J. M. Mariadason, et al. EPHB4 and Survival of Colorectal Cancer Patients. Cancer Res., September 15, 2006; 66(18): 8943 - 8948. [Abstract] [Full Text] [PDF]

				H. Guo, H. Miao, L. Gerber, J. Singh, M. F. Denning, A. C. Gilliam, and B. Wang Disruption of EphA2 Receptor Tyrosine Kinase Leads to Increased Susceptibility to Carcinogenesis in Mouse Skin. Cancer Res., July 15, 2006; 66(14): 7050 - 7058. [Abstract] [Full Text] [PDF]

				D. L. Guo, J. Zhang, S. T. Yuen, W. Y. Tsui, A. S.Y. Chan, C. Ho, J. Ji, S. Y. Leung, and X. Chen Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours Carcinogenesis, March 1, 2006; 27(3): 454 - 464. [Abstract] [Full Text] [PDF]

				H. Clevers and E. Batlle EphB/EphrinB Receptors and Wnt Signaling in Colorectal Cancer Cancer Res., January 1, 2006; 66(1): 2 - 5. [Abstract] [Full Text] [PDF]